If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Transaction in Own Shares

12 Feb 2018 13:22

RNS Number : 6155E
Immunodiagnostic Systems Hldgs PLC
12 February 2018
 

Immunodiagnostic Systems Holdings plc

Transaction in Own Shares

12 February 2018

Immunodiagnostic Systems Holdings plc (IDH.L) ("IDS" or the "Company"), a specialist producer of manual and automated diagnostic testing kits and instrumentation for the clinical and research markets, announces that it has purchased (through Peel Hunt LLP acting as the Company's broker) the following number of its shares of 2p each on the London Stock Exchange. The purchased shares will be held as treasury shares.

The purchases were made pursuant to the buy-back programme announced on 21 June 2017.

Date of purchase:

12 February 2018

Number of shares purchased (aggregated volume):

1,358

Highest price paid per share (pence):

270

Lowest price paid per share (pence):

270

Volume weighted average price paid per share (pence):

270

 

Following the purchase of these shares, IDS holds 40,749 ordinary shares as treasury shares and the Company's issued share capital (excluding shares held as treasury shares) consists of 29,409,426 shares. All of the shares have equal voting rights. This figure 29,409,426 represents the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), detailed information about the individual purchases made by Peel Hunt on the Company's behalf is set out in the schedule below.

For further information:

Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 519 0660

Paul Martin, Group Finance Director

Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel

Oliver Jackson

 

Schedule of Purchases - Individual Transactions

Number of shares purchased

Transaction price(pence per share)

Time of transaction

Trading venue

1,258

270

11:31:51

London Stock Exchange

100

270

11:36:56

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
POSXLLFFVLFLBBB

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.